Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patientsPRNewsWire • 03/30/25
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply ChainInvestors Business Daily • 03/27/25
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?Zacks Investment Research • 03/25/25
Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to KnowZacks Investment Research • 03/21/25
Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/20/25
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA SloganZacks Investment Research • 03/19/25
CGS Transforms Workplace Training with Cicero, a New AI-Driven, Customizable Roleplay PlatformGlobeNewsWire • 03/10/25
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patientsPRNewsWire • 03/09/25